Phase 2, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the efficacy of Linvemastat (FP-020) compared to placebo in patients with T2-high, moderate-to-severe asthma
Latest Information Update: 21 May 2025
At a glance
- Drugs FP 020 (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms SyMMPonia
- Sponsors Foresee Pharmaceuticals
Most Recent Events
- 21 May 2025 New trial record
- 14 May 2025 According to Foresee Pharmaceuticals media release, Toby Maher, M.D., will deliver a keynote presentation titled "SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma" at the Innovation Theater on May 18, 2025. The session will highlight the design and objectives of the multinational syMMPonia Study, a pivotal clinical trial evaluating the efficacy of Linvemastat (FP-020),